| Autor: |
O. P. Shevchenko, A. A. Ulybysheva, N. P. Mozheiko, O. E. Gichkun, E. A. Stakhanova, V. P. Vasilieva, A. O. Shevchenko |
| Jazyk: |
ruština |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
Vestnik Transplantologii i Iskusstvennyh Organov, Vol 22, Iss 1, Pp 8-15 (2020) |
| Druh dokumentu: |
article |
| ISSN: |
1995-1191 |
| DOI: |
10.15825/1995-1191-2020-1-8-15 |
| Popis: |
Objective: to determine the diagnostic value of galectin-3 in transplant recipients with myocardial fibrosis and acute heart transplant rejection, verified by endomyocardial biopsy. Materials and methods. The study included 124 patients with end-stage heart failure. Their ages ranged from 16 to 71 (average 48 ± 12) years, of which 106 (85%) were men and 18 (15%) were women. From 2013 to 2016, these patients underwent a heart transplant procedure at the Shumakov National Medical Research Center of Transplantology and Artificial Organs, Moscow, Russian Federation. Analysis of endomyocardial biopsy specimens was used to verify acute cellular, humoral rejection and myocardial fibrosis of the heart transplant. Severity and nature of fibrosis was evaluated using a qualitative imaging technique. Galectin-3 concentration was measured by enzyme immunoassay using Human Galectin-3 Platinum ELISA reagent kits (Bender MedSystems GmbH, Vienna, Austria). Results. In the long-term post-transplantation period, in comparison with the early post-transplantation period, the number of verified graft myocardial fibrosis increased by 88% in recipients who had acute rejection crises and by 37% in recipients who had no rejection crises. Graft myocardial fibrosis was detected more often in recipients who had acute humoral rejection than in those who had acute cell rejection (92% vs 75% of cases, respectively). Plasma galectin-3 levels in recipients with graft myocardial fibrosis was higher than in recipients without it (p = 0.05 1 year and p = 0.01 1–5 years after heart transplantation). In recipients who had acute rejection crises, the risk of developing graft myocardial fibrosis was 1.64 (RR = 1.64 ± 0.1 [95% CI 1.1–2.2]). Conclusion. Galectin-3 is a biomarker for myocardial fibrosis in acute heart transplant rejection. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
